Previous 10 | Next 10 |
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, 3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2021 financial results and provide an operationa...
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, ...
Amarin received approval to market their drug Vascepa in Europe, but the market shrugged off the news and sent shares lower. As the company struggles with sales and legal battles, a new CEO has been hired. This strategic move could finally unlock the company's value. For fur...
Shares of Amarin (NASDAQ: AMRN) were 10.4% lower as of 11:20 a.m. EDT on Tuesday. The decline came after the drugmaker announced that John Thero plans to retire as president and CEO effective Aug. 1. It's not unusual for changes at the CEO level to cause a biotech stock to f...
Amarin (AMRN) fell 2.6% in premarket trading after the company announced yesterday that CEO John Thero is retiring and will be replaced by Karim Mikhail, who is head of commercial for Europe.The shares may be partly weaker as the transition likely means that any M&A ne...
Gainers: [[OTIC]] +10.4%. [[ASRV]] +5.2%. [[ANGI]] +3.3%. [[HLIT]] +2.7%. [[GDS]] +2.7%.Losers: [[VNET]] -7.7%. [[IMMP]] -5.1%. [[MIND]] -4.6%. [[AMRN]] -4.1%. [[TLSA]] -3.2%. For further details see: OTIC, HLIT, VNET and TLSA among after-hours movers
Amarin (AMRN) announces that John Thero has informed the board of his plan to retire as president and chief executive officer, effective August 1, 2021.The company has appointed Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe, to succ...
John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announ...
Would you want to invest in a biotech with a successful product, surging revenue, and barely any debt? And would your answer change if you heard that the stock's price is less than $7 per share? Hopefully, your answers are "yes," and "no." For investors eyeing Amarin Corporation (...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...